1. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016 
Daniel S.W. Tan, M.B.B.S., MRCP, Sue S. Yom, MD, PhD, Ming S. Tsao, MD, FRCPC, Harvey I. Pass, MD, Karen Kelly, MD, Nir Peled, MD, PhD, Rex C. Yung, MD, Ignacio I. Wistuba, MD, Yasushi Yatabe, MD, PhD, Michael Unger, MD, Philip C. Mack, PhD, Murry W. Wynes, PhD, Tetsuya Mitsudomi, MD, Walter Weder, MD, David Yankelevitz, MD, Roy S. Herbst, MD, PhD, David R. Gandara, MD, David P. Carbone, MD, PhD, Paul A. Bunn, MD, Tony S.K. Mok, MD, Fred R. Hirsch, MD, PhD 
Journal of Thoracic Oncology 
Volume 11, Issue 7, Pages (July 2016)
DOI: /j.jtho
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Delineating disease progression for EGFR-mutant non–small cell lung cancer. TKI, tyrosine kinase inhibitor; PD, progressive disease; SRS, stereotactic radiosurgery; RT, radiotherapy; Cryo, cryotherapy; RFA, radiofrequency ablation; cDNA, complementary DNA; EGFR, epidermal growth factor receptor; MET, MET proto-oncogene, receptor tyrosine kinase; HER2, erb-b2 receptor tyrosine kinase 2 gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; BRAF, B-Raf proto-oncogene, serine of threonine kinase gene. (*If validated and qualified assay is available.)
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions